Shares of HTG Molecular Diagnostics Inc (NASDAQ:HTGM) saw an uptick in trading volume on Wednesday . 4,226,392 shares changed hands during trading, an increase of 963% from the previous session’s volume of 397,629 shares.The stock last traded at $1.95 and had previously closed at $1.84.

Several brokerages recently weighed in on HTGM. Zacks Investment Research raised shares of HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. ValuEngine raised shares of HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Monday, July 17th. Finally, HC Wainwright set a $6.00 price target on shares of HTG Molecular Diagnostics and gave the company a “buy” rating in a research report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the stock. HTG Molecular Diagnostics currently has an average rating of “Hold” and an average target price of $5.75.

The firm’s 50 day moving average is $1.87 and its 200 day moving average is $1.87. The stock’s market capitalization is $22.32 million.

HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its earnings results on Tuesday, August 8th. The medical research company reported ($0.60) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.60). The firm had revenue of $1.76 million for the quarter, compared to analysts’ expectations of $1.80 million. On average, analysts forecast that HTG Molecular Diagnostics Inc will post ($2.29) EPS for the current fiscal year.

In related news, major shareholder Holdings A/S Novo sold 382,437 shares of the stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $1.91, for a total transaction of $730,454.67. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 1,659,998 shares of company stock valued at $3,073,696 in the last three months. 7.60% of the stock is currently owned by corporate insiders.

Institutional investors have recently modified their holdings of the business. UBS Group AG acquired a new position in HTG Molecular Diagnostics during the 1st quarter valued at approximately $137,000. Two Sigma Securities LLC acquired a new position in HTG Molecular Diagnostics during the 1st quarter valued at approximately $150,000. Granahan Investment Management Inc. MA acquired a new position in HTG Molecular Diagnostics during the 1st quarter valued at approximately $228,000. Finally, Vanguard Group Inc. increased its stake in HTG Molecular Diagnostics by 38.9% during the 2nd quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock valued at $359,000 after purchasing an additional 37,841 shares in the last quarter. Institutional investors and hedge funds own 21.67% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “HTG Molecular Diagnostics Inc (HTGM) Sees Unusually-High Trading Volume” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/htg-molecular-diagnostics-inc-htgm-sees-unusually-high-trading-volume/1576476.html.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Receive News & Ratings for HTG Molecular Diagnostics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.